Andrew McMillan

机构：Nottingham University Hospitals NHS Trust · ORCID：0000-0002-8737-8465

发表论文 175 篇 · 总被引 9129 次 · h-index 40

代表论文

• Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data (2021 · Blood Advances · 被引 186)
• A national service for delivering CD19 CAR‐T in large B‐cell lymphoma – The UK real‐world experience (2022 · British Journal of Haematology · 被引 120)
• Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up (2023 · Journal of Clinical Oncology · 被引 80)
• Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study (2021 · Leukemia · 被引 66)
• Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial (2020 · Annals of Oncology · 被引 62)
• Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion (2020 · British Journal of Haematology · 被引 50)